Summary

Report Overview
The Global G7 Spinocerebellar Ataxia Market reached US$ 237.6 million in 2023 and is expected to reach US$ 385.1 million by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031.
Spinocerebellar ataxia (SCA) is an inherited (autosomal dominant), progressive, neurodegenerative, and heterogeneous disease that mainly affects the cerebellum. SCA is a subset of hereditary cerebellar ataxia and is a rare disease. To date, more than 40 distinct genetic SCAs have been identified which are classified according to the genetic loci in order of identification. SCA1 was the first SCA described and then further subtypes are identified sequentially. SCA doesn't compulsorily mean that it is restricted to the cerebellum and spinal cord. It may involve the other parts of the central nervous system as well, such as pontine nuclei, spinal cord, peripheral nerves, cortex, basal ganglia, etc. 
SCA7 is caused by a mutation in the ataxin 7 (ATXN7) gene that leads to an expansion of a CAG trinucleotide repeat. The exact pathogenesis of spinocerebellar ataxia is still not known. However many study series promulgated that common mechanisms of SCA are genetic mutations causing abnormal protein products, transcriptional dysregulation, dysfunction of autophagy, channelopathies, mitochondrial dysfunction, and toxic RNA gain of function.
Market Dynamics: Drivers
Increasing prevalence of G7 spinocerebellar ataxia
The demand for the global G7 spinocerebellar ataxia market is driven by multiple factors. The rising prevalence of G7 spinocerebellar ataxia and technological advancements propel the market growth. 
For instance, according to an article published by nih.gov, SCA7 occurs predominantly in two racial population groups, northern Europeans and Africans. Indeed, SCA7 is the only repeat expansion disease, with the exception of Huntington disease-like 2 (HDL2), with a large number of affected individuals of African racial ancestry. For this reason, a substantial fraction of individuals with SCA7 in the United States are of African racial ancestry. Worldwide, SCA7 is seen in North America, Europe, Eurasia, Australia, South Africa, and South America.
The worldwide prevalence of the disease is estimated to be less than 1/100,000 and it is thought to account for 2-4 % of all forms of spinocerebellar ataxia (up to 7 % in Asian populations). Higher prevalence is found in some populations such as in Scandinavia or South Africa.
Restraints
Factors such as the high cost associated with the treatment, lack of awareness among people, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. There is no cure for G7 spinocerebellar ataxia to date, but managing the symptoms can help make the condition of the disease better.
Market Segment Analysis
The global G7 spinocerebellar ataxia market is segmented based on treatment, end-user, and region.
The segment drugs accounted for approximately 56.3% of the global G7 spinocerebellar ataxia market share
The drugs segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market. 
Amantadine, Buspirone, and Riluzole are the most widely used drugs in treating symptoms and effects of G7 spinocerebellar ataxia market. Amantadine is a member of the class of adamantanes that is used as an antiviral. It has a role as an antiviral drug, a dopaminergic agent, an analgesic, an NMDA receptor antagonist, and a non-narcotic analgesic. It is a primary aliphatic amine and a member of adamantanes. It is a conjugate base of an adamantan-1-aminium. It derives from the hydride of an adamantane.
Buspirone is primarily used to treat generalized anxiety disorder. It is a United States Food and Drug Administration-approved medicine for managing anxiety disorders or the short-term relief of anxiety symptoms.
Market Geographical Analysis
North America accounted for approximately 39.3% of the global G7 spinocerebellar ataxia market market share 
North America region is expected to hold the largest market share over the forecast period. The technological advancements in this region, help to propel the market.
The CRISPR/Cas9 system has been used to delete expanded CAG repeats in induced pluripotent stem cells, and may have future applications in the teeatment of SCA 7. ASO-based treatments are being developed for SCAs, but will require the identification of biomarkers to assess treatment response.
Market Segmentation
By Treatment
Physical and Occupational Therapy
Drugs
Amantadine
Buspirone
Riluzole
Speech and Language Therapy
Visual and Ocular Care
Others 
Gene Therapy
Stem Cell Therapy
By End-User
Hospitals
Specialty Clinics
Others
By Region
North America 
U.S.
Canada
Mexico 
Europe 
Germany
U.K.
France
Spain
Italy
Rest of Europe 
South America 
Brazil
Argentina
Rest of South America
Asia-Pacific 
China
India
Japan
South Korea
Rest of Asia-Pacific 
Middle East and Africa
Market Competitive Landscape
The major global players in the global G7 spinocerebellar ataxia market include Teva Pharmaceuticals Inc., Sanofi, Dynatronics Corporation, Kinetec Medical Products Ltd, EMS Physio Ltd, DJO Global Inc., Enraf-Nonius BV, Zynex Medical Inc., BTL Corporate, Life Care Systems among others.
Why Purchase the Report?
To visualize the global G7 spinocerebellar ataxia market segmentation based on treatment, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global G7 spinocerebellar ataxia market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global G7 spinocerebellar ataxia market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of SCA 7
4.1.1.2. Technological Advancements
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. Lack of Awareness
4.1.2.3. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Treatment
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
6.1.2. Market Attractiveness Index, By Treatment
6.2. Physical and Occupational Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Drugs
6.4. Speech and Language Therapy
6.5. Visual and Ocular Care
6.6. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. UK
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Teva Pharmaceuticals Inc. *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Sanofi
10.3. Dynatronics Corporation
10.4. Kinetic Medical Products Ltd.
10.5. EMS Physio Ltd.
10.6. DJO Global Inc.
10.7. Enraf-Nonius BV
10.8. Zynex Medical Inc.
10.9. BTL Corporate
10.10. Life Care Systems (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us